Jump to content

Draft:Nutcracker Therapeutics

From Wikipedia, the free encyclopedia
  • Comment: To establish notability it needs multiple reliable independent sources with in-depth coverage of the subject not just passing mentions or interviews, sayings of the company, or connected person of the subject. GrabUp - Talk 17:12, 16 May 2024 (UTC)
  • Comment: Press releases, patents and article by staffers are not independent. Stuartyeates (talk) 19:02, 1 December 2023 (UTC)

Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.

NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[2]. As of 2023, NTX-250 is in the preclinical stage of development.

References

[edit]
  1. ^ Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478. PMID 35945442.
  2. ^ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.